Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability

The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characteri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AAPS PharmSciTech 2016-08, Vol.17 (4), p.932-939
Hauptverfasser: Ochi, Masanori, Kimura, Keisuke, Kanda, Atsushi, Kawachi, Takaki, Matsuda, Akitoshi, Yuminoki, Kayo, Hashimoto, Naofumi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 939
container_issue 4
container_start_page 932
container_title AAPS PharmSciTech
container_volume 17
creator Ochi, Masanori
Kimura, Keisuke
Kanda, Atsushi
Kawachi, Takaki
Matsuda, Akitoshi
Yuminoki, Kayo
Hashimoto, Naofumi
description The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and 1 H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.
doi_str_mv 10.1208/s12249-015-0422-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1806080542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1806080542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</originalsourceid><addsrcrecordid>eNp9kUtPxCAUhYnR-P4BbgxLN1Wg0MfSjM9E4ySja0IpTNG2jEDjjL_Enyvz0LhydSH3nHNz8gFwgtE5Jqi48JgQWiYIswRRQpL5FtjHLEVJWaZk-897Dxx4_4oQSXGZ7oI9ktOU4bLYB1_jZuGNtLJRnZGihaKv4bgRrhPSvpleBSPhKP6FDMqZTxGM7aHV8LKzbtbYwcOJbU0Nr4yfKec320fV2nnM6-CHCQ287hvRS7VSedsOq5Cxs9ERFquTk2CdmKo4RWVaExZHYEeL1qvjzTwELzfXz6O75OHp9n50-ZDItMhDovMMV3VNS1prkSOsldBM06LSiiBWy1KXiFRUE1bIOqNZxiQpsryK5SljOUkPwdk6d-bs-6B84J3xUrWt6FVsx3GBMlQgRpdSvJZKZ713SvOZM51wC44RXwLhayA8AuFLIHwePaeb-KHqVP3r-CEQBWQt8HHVT5Xjr3Zwfaz8T-o3LICaqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1806080542</pqid></control><display><type>article</type><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</creator><creatorcontrib>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</creatorcontrib><description>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and 1 H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-015-0422-x</identifier><identifier>PMID: 27435198</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Oral ; Animals ; Biochemistry ; Biological Availability ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Chemistry, Pharmaceutical ; Crystallization - methods ; Drug Compounding - methods ; Drug Stability ; Magnetic Resonance Spectroscopy - methods ; Male ; Pharmacology/Toxicology ; Pharmacy ; Polymers - chemistry ; Polymers - pharmacokinetics ; Polymethacrylic Acids - chemistry ; Rats ; Rats, Sprague-Dawley ; Research Article ; Solubility ; Spectrophotometry, Infrared - methods ; Thiazines - chemistry ; Thiazines - pharmacokinetics ; Thiazoles - chemistry ; Thiazoles - pharmacokinetics</subject><ispartof>AAPS PharmSciTech, 2016-08, Vol.17 (4), p.932-939</ispartof><rights>American Association of Pharmaceutical Scientists 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</citedby><cites>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1208/s12249-015-0422-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1208/s12249-015-0422-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27435198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ochi, Masanori</creatorcontrib><creatorcontrib>Kimura, Keisuke</creatorcontrib><creatorcontrib>Kanda, Atsushi</creatorcontrib><creatorcontrib>Kawachi, Takaki</creatorcontrib><creatorcontrib>Matsuda, Akitoshi</creatorcontrib><creatorcontrib>Yuminoki, Kayo</creatorcontrib><creatorcontrib>Hashimoto, Naofumi</creatorcontrib><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and 1 H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological Availability</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Chemistry, Pharmaceutical</subject><subject>Crystallization - methods</subject><subject>Drug Compounding - methods</subject><subject>Drug Stability</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Male</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Polymers - chemistry</subject><subject>Polymers - pharmacokinetics</subject><subject>Polymethacrylic Acids - chemistry</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Research Article</subject><subject>Solubility</subject><subject>Spectrophotometry, Infrared - methods</subject><subject>Thiazines - chemistry</subject><subject>Thiazines - pharmacokinetics</subject><subject>Thiazoles - chemistry</subject><subject>Thiazoles - pharmacokinetics</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtPxCAUhYnR-P4BbgxLN1Wg0MfSjM9E4ySja0IpTNG2jEDjjL_Enyvz0LhydSH3nHNz8gFwgtE5Jqi48JgQWiYIswRRQpL5FtjHLEVJWaZk-897Dxx4_4oQSXGZ7oI9ktOU4bLYB1_jZuGNtLJRnZGihaKv4bgRrhPSvpleBSPhKP6FDMqZTxGM7aHV8LKzbtbYwcOJbU0Nr4yfKec320fV2nnM6-CHCQ287hvRS7VSedsOq5Cxs9ERFquTk2CdmKo4RWVaExZHYEeL1qvjzTwELzfXz6O75OHp9n50-ZDItMhDovMMV3VNS1prkSOsldBM06LSiiBWy1KXiFRUE1bIOqNZxiQpsryK5SljOUkPwdk6d-bs-6B84J3xUrWt6FVsx3GBMlQgRpdSvJZKZ713SvOZM51wC44RXwLhayA8AuFLIHwePaeb-KHqVP3r-CEQBWQt8HHVT5Xjr3Zwfaz8T-o3LICaqg</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Ochi, Masanori</creator><creator>Kimura, Keisuke</creator><creator>Kanda, Atsushi</creator><creator>Kawachi, Takaki</creator><creator>Matsuda, Akitoshi</creator><creator>Yuminoki, Kayo</creator><creator>Hashimoto, Naofumi</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160801</creationdate><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><author>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological Availability</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Chemistry, Pharmaceutical</topic><topic>Crystallization - methods</topic><topic>Drug Compounding - methods</topic><topic>Drug Stability</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Male</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Polymers - chemistry</topic><topic>Polymers - pharmacokinetics</topic><topic>Polymethacrylic Acids - chemistry</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Research Article</topic><topic>Solubility</topic><topic>Spectrophotometry, Infrared - methods</topic><topic>Thiazines - chemistry</topic><topic>Thiazines - pharmacokinetics</topic><topic>Thiazoles - chemistry</topic><topic>Thiazoles - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ochi, Masanori</creatorcontrib><creatorcontrib>Kimura, Keisuke</creatorcontrib><creatorcontrib>Kanda, Atsushi</creatorcontrib><creatorcontrib>Kawachi, Takaki</creatorcontrib><creatorcontrib>Matsuda, Akitoshi</creatorcontrib><creatorcontrib>Yuminoki, Kayo</creatorcontrib><creatorcontrib>Hashimoto, Naofumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ochi, Masanori</au><au>Kimura, Keisuke</au><au>Kanda, Atsushi</au><au>Kawachi, Takaki</au><au>Matsuda, Akitoshi</au><au>Yuminoki, Kayo</au><au>Hashimoto, Naofumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>17</volume><issue>4</issue><spage>932</spage><epage>939</epage><pages>932-939</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and 1 H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27435198</pmid><doi>10.1208/s12249-015-0422-x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1530-9932
ispartof AAPS PharmSciTech, 2016-08, Vol.17 (4), p.932-939
issn 1530-9932
1530-9932
language eng
recordid cdi_proquest_miscellaneous_1806080542
source MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Administration, Oral
Animals
Biochemistry
Biological Availability
Biomedical and Life Sciences
Biomedicine
Biotechnology
Chemistry, Pharmaceutical
Crystallization - methods
Drug Compounding - methods
Drug Stability
Magnetic Resonance Spectroscopy - methods
Male
Pharmacology/Toxicology
Pharmacy
Polymers - chemistry
Polymers - pharmacokinetics
Polymethacrylic Acids - chemistry
Rats
Rats, Sprague-Dawley
Research Article
Solubility
Spectrophotometry, Infrared - methods
Thiazines - chemistry
Thiazines - pharmacokinetics
Thiazoles - chemistry
Thiazoles - pharmacokinetics
title Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A22%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physicochemical%20and%20Pharmacokinetic%20Characterization%20of%20Amorphous%20Solid%20Dispersion%20of%20Meloxicam%20with%20Enhanced%20Dissolution%20Property%20and%20Storage%20Stability&rft.jtitle=AAPS%20PharmSciTech&rft.au=Ochi,%20Masanori&rft.date=2016-08-01&rft.volume=17&rft.issue=4&rft.spage=932&rft.epage=939&rft.pages=932-939&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-015-0422-x&rft_dat=%3Cproquest_cross%3E1806080542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1806080542&rft_id=info:pmid/27435198&rfr_iscdi=true